Program
GENSCI148
A development code. Also written as “GenSci148 Injection”.
Its studies are mostly in Retinal Vein Occlusion, led by Changchun GeneScience Pharmaceutical.
Furthest: phase 1, since Sep 2, 20261 company-led study, 1 open or runningNext primary completion: Jun 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 11 open or running | phase 1since Sep 2, 2026 | Sep 2, 2026 | Jun 2028phase 1 · NCT07817615 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 2, 2026First study: phase 1 study in Retinal Vein OcclusionFirst studyNCT07817615 · 60 planned · China
Ahead
- Jun 2028Primary completion: phase 1 study in Retinal Vein OcclusionNCT07817615
TargetBeta
ANGPT2 →read by rule
“GenSci148 is a fusion protein that simultaneously targets VEGF-A, VEGF-C, VEGF-D, and Ang-2.”study text, by rule · the study
Other programs on ANGPT2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07817615Retinal Vein Occlusion · China | 1 | Not yet recruiting | Jun 2028 | 60 |
How it is read
Names in the registry
- “GenSci148 Injection”, 1 entry
Codes read as this program: GENSCI148.
Conditions, from the studies’ own filings
- Retinal Vein Occlusion, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.